Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients
NCT02798107
·
clinicaltrials.gov ↗
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
No recruitment
Conditions
Hemorrhage
Interventions
DRUG:
idarucizumab
Sponsor
Boehringer Ingelheim